Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Shares Outstanding (Weighted Average) (2023 - 2025)

Historic Shares Outstanding (Weighted Average) for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $82.4 million.

  • Monte Rosa Therapeutics' Shares Outstanding (Weighted Average) rose 47.08% to $82.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.4 million, marking a year-over-year increase of 47.08%. This contributed to the annual value of $73.9 million for FY2024, which is 4380.23% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Shares Outstanding (Weighted Average) of $82.4 million as of Q3 2025, which was up 47.08% from $82.2 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Shares Outstanding (Weighted Average) registered a high of $82.4 million during Q3 2025, and its lowest value of $49.3 million during Q1 2023.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $66.7 million, with a median of $71.2 million in 2024.
  • Per our database at Business Quant, Monte Rosa Therapeutics' Shares Outstanding (Weighted Average) surged by 6463.28% in 2024 and then soared by 47.08% in 2025.
  • Quarter analysis of 3 years shows Monte Rosa Therapeutics' Shares Outstanding (Weighted Average) stood at $51.4 million in 2023, then soared by 43.8% to $73.9 million in 2024, then grew by 11.48% to $82.4 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $82.4 million for Q3 2025, versus $82.2 million for Q2 2025 and $82.1 million for Q1 2025.